Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

Cited by (502)

Items 101–200 of 502

1. Androgen deprivation therapy complications
   Carolyn A Allan, Veronica Collins, Mark Frydenberg, Robert Ian McLachlan, Kati L. Matthiesson · 2014 · Endocrine Related Cancer
2. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08
   Justin C. Voog, Rebecca Paulus, William U. Shipley, Matthew Raymond Smith, D.G. McGowan, Christopher Uwe Jones, Jean-Paul Bahary, Kenneth Lee Zeitzer, Luís Souhami, Mark H. Leibenhaut et al. · 2015 · European Urology
3. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice
   Anki Knutsson, Sabrina Hsiung, Selvi Celik, Sara Rattik, Ingrid Yao Mattisson, Maria Wigren, Howard I. Scher, Jan Åke Nilsson, Anna Hultgårdh‐Nilsson · 2016 · Scientific Reports
4. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy—A systematic literature review
   Mira Keyes, Gregory Stephen Merrick, Steven Jay Frank, Peter Grimm, Michael J. Zeléfsky · 2017 · Brachytherapy
5. Treatment strategies for high-risk locally advanced prostate cancer
   Seth A. Rosenthal, Howard Mark Sandler · 2010 · Nature Reviews Urology
6. Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer: Prevention and Management
   Petros Sountoulides, Thomas Rountos · 2013 · ISRN Urology
7. Conventional Treatments of Localized Prostate Cancer
   Marc Zerbib, Michael J. Zeléfsky, Celestia S. Higano, Peter R. Carroll · 2008 · Urology
8. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.
   C. Cattabiani, Shehzad Sultan Basaria, Gian Paolo Ceda, Michele Luci, A Vignali, Fulvio Lauretani, Giorgio Valenti, Riccardo Volpi, Marcello Giuseppe Maggio · 2012 · PubMed
9. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer
   Thiago Gagliano‐Jucá, Thomas G. Travison, Philip W. Kantoff, Paul Linh Nguyen, Mary‐Ellen Taplin, Adam Stuart Kibel, Grace Tzu-Wei Huang, Richelle Bearup, Haley Schram, Robert Manley et al. · 2018 · Journal of the Endocrine Society
10. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
    Zaid Ali Siddiqui, Daniel J. Krauss · 2018 · Translational Andrology and Urology
11. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate‐risk disease
    Florence K. Keane, Ming‐Hui Chen, Danjie Zhang, Marian J. Loffredo, Philip W. Kantoff, Andrew A. Renshaw, Anthony Victor D'Amico · 2014 · Cancer
12. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention
    Vivek Narayan, Bonnie Ky · 2018 · Annual Review of Medicine
13. Cardiovascular Toxicities of Androgen Deprivation Therapy
    Azariyas A. Challa, Adam Christopher Calaway, Jennifer Cullen, Jorge García, Nihar R. Desai, Neal L. Weintraub, Anita M Deswal, Shelby Kutty, Ajay Vallakati, Daniel Addison et al. · 2021 · Current Treatment Options in Oncology
14. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer
    Chiara Melloni, Susan F. Slovin, Allan Blemings, Shaun G. Goodman, Christopher P. Evans, Jan Åke Nilsson, Deepak L. Bhatt, Konstantin Zubovskiy, Tine Kold Olesen, Klaus A. Dugi et al. · 2020 · JACC CardioOncology
15. Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
    Paul Linh Nguyen, Ming‐Hui Chen, Clair J. Beard, W. Warren Suh, Andrew A. Renshaw, Marian J. Loffredo, Elizabeth McMahon, Philip W. Kantoff, Anthony Victor D'Amico · 2009 · International Journal of Radiation Oncology*Biology*Physics
16. Management of localized prostate cancer in senior adults: the crucial role of comorbidity
    John M. Fitzpatrick · 2008 · British Journal of Urology
17. Testosterone, cardiomyopathies, and heart failure
    Rodica Diaconu, Ionuţ Donoiu, Oana Mirea, Tudor Adrian Bălşeanu · 2021 · Asian Journal of Andrology
18. Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death
    Anthony Victor D'Amico, Ming‐Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff · 2009 · International Journal of Radiation Oncology*Biology*Physics
19. Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial
    Hiroyuki Konaka, Shin Egawa, Shiro Saito, Atsunori Yorozu, Hiroyuki Takahashi, Keiko Miyakoda, Masanori Fukushima, Takushi Dokiya, Hidetoshi Yamanaka, Nelson Neal Stone et al. · 2012 · BMC Cancer
20. How can we make cancer survival statistics more useful for patients and clinicians: An illustration using localized prostate cancer in Sweden
    Sandra Eloranta, Jan Adolfsson, Paul C. Lambert, Pär E. Stattin, Olof Akre, Therése Andersson, Paul William Dickman · 2013 · Cancer Causes & Control
21. A natural history of weight change in men with prostate cancer on androgen‐deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database
    Howard S. Kim, Daniel Martins Moreira, Matthew Raymond Smith, Joseph C. Presti, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling, Stephen J. Freedland · 2010 · British Journal of Urology
22. Exercise therapy across the prostate cancer continuum
    Jerome Antonelli, Stephen J. Freedland, Lee W. Jones · 2009 · Prostate Cancer and Prostatic Diseases
23. Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer
    Gabriela Silvia Gheorghe, Andreea Simona Hodorogea, Ana Ciobanu, Ioan Tiberiu Nanea, Andrei Cristian Dan Gheorghe · 2021 · Current Oncology
24. Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
    Giovanni Corona, Mauro Gacci, Elisabetta Baldi, Rosa Mancina, Gianni Forti, Mario Maggi · 2012 · The Journal of Sexual Medicine
25. Prostate cancer in the elderly
    Hans Heinzer A, Thomas P Steuber · 2009 · Urologic Oncology Seminars and Original Investigations
26. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
    Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Dilip Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A. Singer, Mark N. Stein, James Andrew Eastham, Peter T. Scardino et al. · 2018 · Cancer
27. Future Prospects for Luteinizing Hormone-Releasing Hormone Analogues in Prostate Cancer Treatment
    Hideyuki Akaza · 2010 · Pharmacology
28. Management of metastatic prostate cancer: the crucial role of geriatric assessment
    Jean‐Pierre Droz, A. Chaladaj · 2008 · British Journal of Urology
29. Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases
    Gincy George, Hans Garmo, Lucie‐Marie Scailteux, Frédéric Balusson, Greet De Coster, Harlinde De Schutter, Josephina G. Kuiper, Emmanuel Oger, Julie Verbeeck, Mieke Van Hemelrijck · 2020 · International Journal of Cancer
30. Combining Radiation Therapy and Androgen Deprivation for Localized Prostate Cancer—A Critical Review
    Alan Dal Pra, Fabio Cury, Luís Souhami · 2010 · Current Oncology
31. Testosterone Recovery After Prolonged Androgen Suppression in Patients With Prostate Cancer
    Frederick H. Yoon, Sandra L. Gardner, Cyril E Danjoux, Gerard Morton, Patrick Cheung, Richard C. Choo · 2008 · The Journal of Urology
32. Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study
    Dong‐Yi Chen, Lai‐Chu See, Jia‐Rou Liu, Cheng‐Keng Chuang, See‐Tong Pang, Ching‐Lin Hsieh, Ming‐Shien Wen, Tien‐Hsing Chen, Yung‐Chang Lin, Chuang‐Chi Liaw et al. · 2017 · Journal of Clinical Oncology
33. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer
    Anthony Victor D'Amico, Ming‐Hui Chen, Andrew A. Renshaw, Marian J. Loffredo, Philip W. Kantoff · 2008 · Cancer
34. Cardiovascular risk with androgen deprivation therapy for prostate cancer: Potential mechanisms
    Åsa Tivesten, Jehonathan H. Pinthus, Noel William Clarke, Wilhelmina Duivenvoorden, Jan Åke Nilsson · 2015 · Urologic Oncology Seminars and Original Investigations
35. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?
    Farid Saad · 2012 · Diabetes/Metabolism Research and Reviews
36. Australian & New Zealand Faculty of Radiation Oncology Genito‐Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma
    AJ Hayden, Jarad M. Martin, Andrew B. Kneebone, Margot Lehman, K.L. Wiltshire, Marketa Skala, David Christie, Philip Vial, R McDowall, K‐H Tai · 2010 · Journal of Medical Imaging and Radiation Oncology
37. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer
    Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà, Ottavio DE COBELLI, Franco Nolè · 2015 · European Journal of Cancer
38. Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective
    Suzanne Biehn Stewart, Stephen Anthony Boorjian · 2014 · Urologic Oncology Seminars and Original Investigations
39. Challenges of managing elderly men with prostate cancer
    Gautam Gopalji Jha, Vidhu Anand, Ayman Soubra, Badrinath R. Konety · 2014 · Nature Reviews Clinical Oncology
40. Short‐ vs long‐term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node‐negative high‐risk adenocarcinoma of the prostate
    Anthony Victor D'Amico, James William Denham, M. Bolla, Laurence Collette, David S. Lamb, Keen‐Hun Tai, Allison Steigler, Ming‐Hui Chen · 2007 · Cancer
41. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure
    Daniel Abido Galvao, Dennis R. Taaffe, Nigel A. Spry, DJ Joseph, Robert Usher Newton · 2009 · Prostate Cancer and Prostatic Diseases
42. Pharmacotherapeutic Management of Locally Advanced Prostate Cancer
    Jarad M. Martin, Stéphane Supiot, Dominik Berthold · 2011 · Drugs
43. Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer
    James L. Gulley, Jeanny B. Aragon‐Ching, Seth M. Steinberg, Maha Hussain, Oliver A. Sartor, Celestia S. Higano, Daniel Peter Petrylak, Gurkamal S. Chatta, Philip Martin Arlen, William Douglas Figg et al. · 2008 · The Journal of Urology
44. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
    Wook Nam, Se Young Choi, Sang Jun Yoo, Jeman Ryu, Jae Hoon Lee, Yoon Soo Kyung, Jae Hyeon Han, Dalsan You, In Gab Jeong, Jun Hyuk Hong et al. · 2018 · Korean journal of urology
45. Androgen deprivation therapy and cardiovascular disease
    Chiara Melloni, Matthew T. Roe · 2019 · Urologic Oncology Seminars and Original Investigations
46. Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
    Hendrik Van Poppel, Per‐Anders Abrahamsson · 2020 · International Journal of Urology
47. Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease
    Abdulmaged M. Traish, Bassima Abdallah, George W. Yu · 2011 · Hormone Molecular Biology and Clinical Investigation
48. High-Dose Isoflavones Do Not Improve Metabolic and Inflammatory Parameters in Androgen-Deprived Men With Prostate Cancer
    Napora, J. K., Short, R. G., Muller, D. C., Carlson, O. D., Odetunde, J. O., Xu, X., Carducci, M., Travison, T. G., Maggio, M., Egan, J. M. et al. · 2011 · Journal of Andrology
49. Triptorelin in the Management of Prostate Cancer
    Guillaume Ploussard, Pierre Mongiat-Artus · 2012 · Future Oncology
50. Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects
    Ginah Nightingale, Rowena N Schwartz, Ekaterina Kachur, Brianne N. Dixon, Christine Cote, Ashley Barlow, Brooke Barlow, Patrick J. Medina · 2018 · Journal of Geriatric Oncology
51. Prospective study of exercise intervention in prostate cancer patients on androgen deprivation therapy
    Nadine Beydoun, Joseph A. Bucci, Yaw Sinn Chin, Nigel A. Spry, Robert Usher Newton, Daniel Abido Galvao · 2013 · Journal of Medical Imaging and Radiation Oncology
52. Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
    Andrew J. Armstrong, Vinnie Y.T. Liu, Ramprasaath R. Selvaraju, Emmalyn Chen, Jeffry Simko, Sandy DeVries, Oliver A. Sartor, Howard Mark Sandler, Osama Mohamad, Huei-Chung Rebecca Huang et al. · 2025 · Journal of Clinical Oncology
53. Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement
    Landon W Trost, Ege Can Şerefoğlu, Ahmet Gökçe, Brian J. Linder, Alton Oliver Sartor, Wayne J.G. Hellstrom · 2013 · The Journal of Sexual Medicine
54. The Effects of Androgen Deprivation Therapy on Lipid Metabolism and Body Composition in Japanese Patients with Prostate Cancer
    Kazumasa Torimoto, Shoji Samma, Yoriaki Kagebayashi, Yoshitomo Chihara, Nobumichi Tanaka, Akihide Hirayama, Kiyohide Fujimoto, Yoshihiko Hirao · 2011 · Japanese Journal of Clinical Oncology
55. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications
    Adam Rea Kuykendal, Laura H. Hendrix, Ramzi George Salloum, Paul Alphonso Godley, R. C. Chen · 2013 · Annals of Oncology
56. Impact of androgen deprivation therapy on mood, cognition, and risk for AD
    Monique M. Cherrier, Celestia S. Higano · 2019 · Urologic Oncology Seminars and Original Investigations
57. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study
    Nigel A. Spry, Dennis R. Taaffe, PAUL J. ENGLAND, J S Judge, D A Stephens, Carolyn J. Peddle‐McIntyre, Michael Kevin Baker, Robert Usher Newton, Daniel Abido Galvao · 2012 · Prostate Cancer and Prostatic Diseases
58. A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial
    Daniel Abido Galvao, Nigel A. Spry, Dennis R. Taaffe, James William Denham, David John Joseph, David S. Lamb, Greg Levin, Gillian M. Duchesne, Robert Usher Newton · 2009 · BMC Cancer
59. Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer
    Valentina Milazzo, Nicola Cosentino, Jeness Campodonico, Claudia Lucci, Daniela Maria Cardinale, Carlo Maria Cipolla, Giancarlo Marenzi · 2020 · Journal of Clinical Medicine
60. Cardiovascular risk during hormonal treatment in patients with prostate cancer
    Hendrik Van Poppel · 2011 · Cancer Management and Research
61. Radiation therapy for prostate cancer after prostatectomy: adjuvant or salvage?
    Amit R. Patel, Andrew J. Stephenson · 2011 · Nature Reviews Urology
62. Metabolic Syndrome and Prostate Cancer: A Review
    Jenny P. Nobes, Stephen E M Langley, Robert W Laing · 2008 · Clinical Oncology
63. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?
    Galvão, Daniel A, Newton, Robert U, Taaffe, Dennis R, Spry, Nigel · 2008 · Nature Clinical Practice Urology
64. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease
    Kathleen Hwang, Martin M. Miner · 2014 · Asian Journal of Andrology
65. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status
    Tyler R. McClintock, Nicolas von Landenberg, Alexander Putnam Cole, Stuart R. Lipsitz, Philipp Gild, Maxine Sun, Sean A. Fletcher, Florian Roghmann, Mani Menon, Paul Linh Nguyen et al. · 2018 · Annals of Surgical Oncology
66. Reduced Cardiorespiratory Fitness and Increased Cardiovascular Mortality After Prolonged Androgen Deprivation Therapy for Prostate Cancer
    Jingyi Gong, David Payne, Jesse Pittard Caron, Camden Phillip Bay, Bradley Alexander McGregor, Jon Mark Hainer, Ann H. Partridge, Tomas G. Neilan, Marcelo F. Di Carli, Anju Nohria et al. · 2020 · JACC CardioOncology
67. Phase I/II Study of Biweekly Paclitaxel and Radiation in Androgen-Ablated Locally Advanced Prostate Cancer
    Nicholas J Sanfilippo, Samir S. Taneja, Abraham Chachoua, Herbert Lepor, Silvia Chiara Formenti · 2008 · Journal of Clinical Oncology
68. Androgen Deprivation Therapy for Prostate Cancer Does Not Increase Cardiovascular Mortality in the Long Term
    Chantelle Wilcox, Allison Kautto, Allison Steigler, James William Denham · 2012 · Oncology
69. The Effects of Androgen Deprivation Therapy on Cardiac Function and Heart Failure: Implications for Management of Prostate Cancer
    Scott Edelman, Javed Butler, Bruce Warren Hershatter, Mohammad Khurram Khan · 2014 · Clinical Genitourinary Cancer
70. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer
    Tiffany Daly · 2019 · World Journal of Urology
71. Parenteral oestrogen in the treatment of prostate cancer: a systematic review
    Gill Norman, Michael Emmans Dean, Ruth Elizabeth Langley, Zachary Hodges, G Ritchie, Mahesh Parmar, Matthew Robert Sydes, P D Abel, Alison J. Eastwood · 2008 · British Journal of Cancer
72. Dose‐dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events
    Marianne Schmid, Jesse D. Sammon, Gally Reznor, Victor Kapoor, Jacqueline M. Speed, Firas Abdollah, Akshay Sood, Felix K.‐H. Chun, Adam Stuart Kibel, Mani Menon et al. · 2015 · British Journal of Urology
73. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients
    Chengyue Jin, Yu Fan, Y Meng, Cheng Shen, Yang Wang, Sanyuan Hu, Can Cui, Tao Xu, W Yu, Jie Jin · 2016 · Prostate Cancer and Prostatic Diseases
74. Radical prostatectomy in older men: survival outcomes in septuagenarians and octogenarians
    Phillip Martin Pierorazio, Elizabeth B. Humphreys, Patrick C. Walsh, Alan Wayne Partin, Misop Han · 2010 · British Journal of Urology
75. Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010
    Harvey Charles Quon, D. Andrew Loblaw · 2010 · Current Oncology
76. Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review
    Wayne J.G. Hellstrom, Darius A. Paduch, Craig F. Donatucci · 2010 · International Urology and Nephrology
77. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management
    Howard S. Kim, Stephen J. Freedland · 2010 · Current Opinion in Supportive and Palliative Care
78. Androgen Deficiency in Aging and Metabolically Challenged Men
    Jeremy B. Shelton, Jacob Rajfer · 2011 · Urologic Clinics of North America
79. Incidental Testicular Irradiation From Prostate IMRT: It All Adds Up
    Christopher R. King, Peter G. Maxim, Annie Hsu, Daniel Stuart Kapp · 2009 · International Journal of Radiation Oncology*Biology*Physics
80. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy
    Vivek Narayan, Neha Vapiwala, Rosemarie Mick, Pearl Subramanian, John Paul Christodouleas, Justin E. Bekelman, Curtiland Deville, Ramji Ramaswamy Rajendran, Naomi Balzer Haas · 2016 · International Journal of Radiation Oncology*Biology*Physics
81. “Staging the Aging” When Considering Androgen Deprivation Therapy for Older Men With Prostate Cancer
    William Dale · 2009 · Journal of Clinical Oncology
82. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study
    Paolo Dell’Oglio, Hiba Abou‐Haidar, Sami‐Ramzi Leyh‐Bannurah, Zhe Tian, Alessandro Larcher, Giorgio Gandaglia, Nicola Fossati, Shahrokh François Shariat, Umberto Capitanio A, Alberto Briganti et al. · 2016 · European Urology
83. Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta‐analysis and systematic review
    Zhen Chang Liang, Jun Wei Zhu, Xiaoxin Duo, Shangheng Shi, Yawei Xu, Yongjiao Yang, Rui Hu, Yi Lu, Wei Zhang, Ningjing Ou et al. · 2019 · Andrology
84. Androgen Deprivation Therapy: Minimizing Exposure and Mitigating Side Effects
    Miren Gaztañaga, Juanita Mary Crook · 2012 · Journal of the National Comprehensive Cancer Network
85. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review
    Claude C. Schulman, Jacques Irani, Juan Moróte, Jack A. Schalken, Francesco Montorsi, Piotr L Chłosta, Axel Heidenreich · 2010 · European Urology Supplements
86. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy
    A.M. Dosoretz, Ming‐Hui Chen, Sharon A. Salenius, Rudolf H. Ross, Daniel E. Dosoretz, Michael J. Katin, Constantine Anastasios Mantz, Bruce M. Nakfoor, Anthony Victor D'Amico · 2010 · Cancer
87. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden
    David Robinson, Hans Garmo, Bertil Lindahl, Mieke Van Hemelrijck, Jan Adolfsson, Ola Bratt A, Lars Holmberg, Pär E. Stattin · 2011 · International Journal of Cancer
88. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors
    Matthew R. Smith · 2008 · Current Urology Reports
89. Cardiac and Cognitive Effects of Androgen Deprivation Therapy: Are They Real?
    Shabbir M.H. Alibhai, Hassanabbas Z. Mohamedali · 2010 · Current Oncology
90. Androgen‐suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    Julia H. Hayes, Ming‐Hui Chen, Brian Joseph Moran, Michelle H. Braccioforte, Daniel E. Dosoretz, Sharon A. Salenius, Michael J. Katin, Rudi Ross, Toni K. Choueiri, Anthony Victor D'Amico · 2010 · British Journal of Urology
91. Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
    Giovanni Corona, Sandra Filippi, Nicola Bianchi, Mauro Dicuio, Giulia Rastrelli, Sergio Concetti, Alessandra Sforza, Mario Maggi · 2020 · The World Journal of Men s Health
92. Pathologic effects of testosterone deprivation
    Preston C. Sprenkle, Harry Fisch · 2007 · Current Opinion in Urology
93. Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
    Seungtaek L. Choi, Andrew Lee · 2011 · Drug Healthcare and Patient Safety
94. Management of Older Men With Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity
    Karen Elizabeth Hoffman · 2012 · Seminars in Radiation Oncology
95. Innovations in the systemic therapy of prostate cancer
    Dale Randall Shepard, Derek Raghavan · 2009 · Nature Reviews Clinical Oncology
96. All-cause mortality as an outcome in epidemiologic studies: proceed with caution
    Noel S. Weiss · 2014 · European Journal of Epidemiology
97. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years
    Firas Abdollah, Jesse D. Sammon, Gally Reznor, Anil K. Sood, Marianne Schmid, Dane E. Klett, Maxine Sun, Ayal Aaron Aizer, Toni K. Choueiri, Jim C. Hu et al. · 2015 · European Journal of Surgical Oncology
98. Decreasing Use of Luteinizing Hormone-Releasing Hormone Agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration Claims Analysis
    Steven Lee Chang, Joseph C. Liao, Rajesh Shinghal · 2009 · The Journal of Urology
99. Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?
    Robert Usher Newton, Dennis R. Taaffe, Nigel A. Spry, Prue Cormie, Suzanne K. Chambers, Robert Alexander Gardiner, David Shum, David John Joseph, Daniel Abido Galvao · 2012 · BMC Cancer
100. Inhibition of Progression of Androgen-Dependent Prostate LNCaP Tumors to Androgen Independence in SCID Mice by Oral Caffeine and Voluntary Exercise
     Xi Zheng, Xiaoxing Cui, Mou‐Tuan Huang, Yue Liu, George C. Wagner, Yong Lin, Weichung Joe Shih, Mao‐Jung Lee, Chung Shu Yang, Allan H. Conney · 2012 · Nutrition and Cancer